Large gap with delayed quotes
|
Last quote
10/17/2026
-
02:00:00
|
Bid
10/16/2026 -
21:59:55
|
Bid Volume |
Ask
10/16/2026 -
21:59:55
|
Ask Volume |
|---|---|---|---|---|
|
533.12
-8.39
(
-1.55% )
|
532.90
|
40 |
533.58
|
40 |
Analysis date: 13.10.2026
Global Evaluation
Positive
Positive
The stock is classified in the positive zone since 02.10.2026.
Quality
Very strong
Very strong
Four stars since 06.10.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 06.10.2026 at a price of 541.62.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 02.10.2026.
4wk Rel Perf
7.37%
7.37%
The four-week dividend-adjusted overperformance versus SP500 is 7.37%.
Risk
Low
Low
The stock has been on the low-sensitivity level since 18.09.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.80%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.70%.
Mkt Cap in $bn
23.59
23.59
With a market capitalization >$8bn, UNITED THERAPEUTICS is considered a large-cap stock.
G/PE Ratio
1.23
1.23
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
11.24
11.24
The estimated PE is for the year 2029.
LT Growth
13.78%
13.78%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
11
11
Over the last seven weeks, an average of 11 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
33
33
For 1% of index variation, the stock varies on average by 0.33%.
Correlation
0.12
0.12
Stock movements are totally independent of index variations.
Value at Risk
65.21
65.21
The value at risk is estimated at USD 65.21. The risk is therefore 12.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
08.06.2005
08.06.2005